Thymosin beta-4Actin-binding peptide · research
Thymosin beta-4 helps regulate actin, a structural protein involved in cell movement. Research on tissue repair includes local eye and wound treatments, which do not automatically support systemic injections for injuries.
What is Thymosin beta-4?
Thymosin beta-4 is a naturally occurring peptide involved in the organisation of actin, a structural protein inside cells. It has been investigated in tissue-repair research.
How it works
It binds actin and participates in processes related to cell movement. Those processes matter in wound repair, but a biological role does not establish the effect of administering extra peptide.
Effects studied
What does the evidence show?
Mechanistic work and local tissue-repair studies
A cellular role with several possibilities
Thymosin beta-4 is a naturally occurring peptide that binds actin. Cell movement is involved in wound repair, so researchers have explored whether changing this system could help damaged tissues recover. That biological rationale is a reason to investigate, rather than a result in an injured person.
Where the research becomes more specific
The retained material includes work involving corneal and skin repair. A preparation applied to the eye or a wound is delivered to a particular tissue and measured against a particular healing outcome. Its exposure pattern differs substantially from injecting a product with the aim of repairing a tendon or muscle. 1 2 3
Why TB-500 needs its own entry
Commercial use of “TB-500” can blur the distinction between the full thymosin beta-4 sequence and a shorter fragment. Comparing studies requires identifying the actual sequence, formulation and route. Listing the names together in a catalogue does not make their evidence transferable.
What would support a recovery claim
A sports-injury trial would need to define the injury, provide comparable rehabilitation and measure function, return to activity and recurrence. Local wound findings do not answer those questions. Safety assessment also needs to address biological activity, product identity and immune or injection reactions. A “research” label resolves none of these issues.
Safety & status
Safety depends on the sequence, preparation and route. Immune reactions and injection-related complications need separate assessment for systemic products.
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Is it the same as TB-500?
Not reliably by label alone. TB-500 marketing can refer to the full peptide or a shorter fragment; the actual sequence needs identifying.
Do eye studies support sports-injury injections?
No. Corneal treatment and systemic treatment of an injured tendon involve different exposures and clinical outcomes.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
Related names & questions
Connections help distinguish compounds and uses; they do not imply equivalent benefits.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.